8RK59 is a PARK7 inhibitor.

XL-188 is a highly potent and selective inhibitor of USP7. XL188 inhibited USP7 catalytic domain and full-length enzyme with IC50 values of 193 and 90 nM, respectively. XL188 Promotes USP7-Dependent Loss of HDM2 and Increase of p53 and p21. XL188 represents one of only a small set of mammalian DUB inhibitors with low nanomolar potency and a high degree of selectivity relative to other DUBs

FT709是一种选择性的去泛素化酶USP9X抑制剂(IC50=82 nM)，能够降低Makorins和ZNF598的水平，损伤核糖体质量控制途径。

RA-9 是一种高选择性蛋白酶体相关的 DUBs 抑制剂，具有良好的毒性和抗癌活性。它阻断泛素依赖性蛋白降解而不影响 20S 蛋白酶体蛋白水解活性。它诱导卵巢癌细胞内质网应激反应，选择性诱导卵巢癌细胞株和供体原代培养细胞凋亡。

HBX 19818 是一种特异性泛素特异性蛋白酶 7 (USP7) 抑制剂，IC50值为 28.1 μM。

STD1T 是一种具有选择性和有效性的脱泛素酶 USP2a 抑制剂，具有潜在的抗癌活性，可降低 HCT116 结肠和 MCF-7 乳腺癌细胞中的细胞周期蛋白 D1 蛋白水平。

USP8-IN-2 是一种有效的去泛素化酶 USP7和USP8 抑制剂，对USP8D 的IC50为4.0 μM。USP8-IN-2是治疗癌症和病毒感染的潜在化合物。

USP8-IN-1 是USP8的抑制剂，IC50为 1.9 μM。USP8-IN-1 抑制 H1975 细胞生长，GI50为 82.04 μM。

LXE408 is an orally active, kinetoplastid-selective proteasome inhibitor, exhibiting non-competitive inhibitory effects. It demonstrates an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. Moreover, LXE408 shows limited ability to traverse the blood-brain barrier. Hence, LXE408 holds promise for advancing research in the field of visceral leishmaniasis (VL).